Evidence map›Paper›PMID 30898838›Full record

ArticleCancer research2019

Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.

Colles Price, Stanley Gill, Zandra V Ho, Shawn M Davidson, Erin Merkel, James M McFarland, Lisa Leung, Andrew Tang, Maria Kost-Alimova, Aviad Tsherniak and 3 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Notch signaling, hypoxia, and cancer.Frontiers in oncology · 2023
    Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Colles PriceBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Stanley GillBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Zandra V HoBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0003-4046-0266
Shawn M DavidsonBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Erin MerkelBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
James M McFarlandBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Lisa LeungBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Andrew TangBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Maria Kost-AlimovaBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Aviad TsherniakBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-3797-1877
Oliver JonasBroad Institute of Harvard and MIT, Cambridge, Massachusetts.
Francisca VazquezBroad Institute of Harvard and MIT, Cambridge, Massachusetts.ORCID 0000-0002-2857-4685
William C HahnBroad Institute of Harvard and MIT, Cambridge, Massachusetts. william_hahn@dfci.harvard.edu.
Broad Institute · US

Funding

Image Guided Therapy Center - Ultrasound-based sensor system for the monitoring of COVID-19 patientsP41EB015898 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI TEMPANY, CLARE M · 2012 to 2021
$18.9M
Tumor Cell Biology Training ProgramT32CA009361 · NCI · DANA-FARBER CANCER INSTITUTE · PI GRAY, NATHANAEL SCHIANDER · 1985 to 2015
$8.9M
The Dana-Farber Cancer Institute Cancer Target Discovery and Development CenterU01CA176058 · NCI · DANA-FARBER CANCER INST · PI HAHN, WILLIAM C. · 2013 to 2021
$7.8M
In Situ characterization and manipulation of tumor immune cell metabolomics using implantable microdevicesR01CA223150 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI JONAS, OLIVER · 2018 to 2022
$1.9M
NCI NIH HHS R01 CA223150NCI NIH HHS T32 CA009361NCI NIH HHS U01 CA176058NIBIB NIH HHS P41 EB015898
6 · The paper itself

Abstract

We hypothesized that candidate dependencies for which there are small molecules that are either approved or in advanced development for a nononcology indication may represent potential therapeutic targets. To test this hypothesis, we performed genome-scale loss-of-function screens in hundreds of cancer cell lines. We found that knockout of

Indexed as

Genome-Wide Association StudyCell Line, TumorCRISPR-Cas SystemsFemaleHumansHypoxia-Inducible Factor-Proline DioxygenasesOvarian NeoplasmsRNA InterferenceEGLN1 protein, humanHypoxia-Inducible Factor-Proline Dioxygenases

Identifiers

PMID30898838
PMCPMC6522283
OpenAlexW2924347575

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.